Here are five points:
1. Christopher McNulty was named senior vice president of business development and investor relations.
2. Prior to this promotion, Mr. McNulty was vice president of vice president of business development and investor relations.
3. He received an MBA from Harvard Business School.
4. Alex Aimetti, PhD, was appointed to senior director of medical education and scientific support.
5. Prior to this promotion, Dr. Aimetti served as associate R&D director of biomaterials.
6. Dr. Aimetti received a doctorate in chemical and biological engineering from the University of Colorado Boulder.
“Upon assuming his investor relations responsibilities, Chris has been a key member of the team responsible for our expanded interaction with the financial community, recent capital raises, and our listing on the Nasdaq,” said Mark Perrin, CEO and chairman of InVivo. “Alex will advance scientific communications related to our pipeline by leading the design and management of medical education programs…”
More articles on devices:
LDR revenue up 19.4%, net loss at $5.8M: 10 key notes
InVivo’s Q2 net loss hits $10.4M as spinal cord injury trial shows early success: 5 things to know
St. Jude Medical names Zimmer Biomet’s David Dvorak to board — 5 key points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
